TEMPEST THERAPEUTICS, INC.
Profile
Company Names
TEMPEST THERAPEUTICS, INC.
OVASCIENCE, INC.
Addresses
2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CA 94005
2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, CA 94005
7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO, CA 94080
215 FIRST STREET, SUITE 240, CAMBRIDGE, MA 02142
800 BOYLSTON STREET, SUITE 1555, BOSTON, MA 02199
Phone Numbers
415-798-8589
(415) 798-8589
617-902-0682
617-351-2590
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY
Year Incorporated:
2011
State Incorporated:
DELAWARE
Total Amount Raised:
$98,230,655.00
Number of Funding Rounds:
6
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
6
2026-05-29
$4,056,552.00
$4,056,552.00
$0.00
Equity
5
2026-03-20
$1,999,539.00
$1,999,539.00
$0.00
Equity
4
2022-04-26
$15,000,000.00
$15,000,000.00
$0.00
Equity
3
2013-03-18
$34,999,920.00
$34,999,920.00
$0.00
Equity
2
2012-06-21
$4,936,547.00
$4,936,547.00
$0.00
Equity
1
2012-03-29
$37,238,097.00
$37,238,097.00
$0.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
RICHARD
ALDRICH
DIRECTOR
MATTHEW
ANGEL
EXECUTIVE OFFICER, DIRECTOR
MICHELLE
DIPP
EXECUTIVE OFFICER, DIRECTOR
OVASCIENCE, INC.
| AXIAL BIOTHERAPEUTICS, INC.
| GAP COINVESTMENTS III, LLC
| GAP COINVESTMENTS IV, LLC
| GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.
| GENERAL ATLANTIC PARTNERS 100, L.P.
| GENERAL ATLANTIC PARTNERS (BERMUDA) IV, L.P.
| GENERAL ATLANTIC INVESTMENT PARTNERS 2017, L.P.
| PATHAI, INC.
| BIOSPRING PARTNERS ABZ FUND III, L.P.
| BIOSPRING PARTNERS TECH I, L.P.
| BIOSPRING PARTNERS ABZ FUND IV, L.P.
| BIOSPRING PARTNERS FUND, L.P.
| BIOSPRING PARTNERS ABZ FUND, L.P.
| BIOSPRING PARTNERS ABZ FUND V, L.P.
MICHAEL
FLANAGAN
EXECUTIVE OFFICER
STEPHEN
KRAUS
DIRECTOR
ALISON
LAWTON
EXECUTIVE OFFICER
THOMAS
MALLEY
DIRECTOR
CHRISTINE
PELLIZZARI
DIRECTOR
JOHN
SIMON
DIRECTOR
IWALK, INC.
| GO2 MEDIA, INC.
| CARDICA INC
| ACTON PHARMACEUTICALS, INC.
| PINNACLE PROPERTIES-EVERETT, LLC
| WIND POWER HOLDINGS INC
| PAYDIANT, INC.
| JUMPTAP INC
| LIAISON TECHNOLOGIES, INC.
| CYPHY WORKS, INC,
| OVASCIENCE, INC.
| SIGMA PRIME PARTNERS IX, L.P.
| SIGMA PRIME ASSOCIATES IX, L.P.
| SIGMA PRIME ENTREPRENEURS IX, L.P.
| Q FACTOR COMMUNICATIONS CORP
| BLUECONIC HOLDING, INC.
| CODESHIP, INC.
| NTOGGLE, INC.
| CODESHIP INC.
| NINE POINT ENERGY HOLDINGS, INC.
| AZURE SOURCE CAPITAL, LLC
| ACTIO ANALYTICS INC.
| TOTAL IMPACT NOTES PUBLIC BENEFIT LLC
CHRISTOPH
WESTPHAL
DIRECTOR
VERASTEM, INC.
| OVASCIENCE, INC.
| FLEX PHARMA, INC.
| RECROS MEDICA, INC.
| PYXIS ONCOLOGY, INC.
| TSCAN THERAPEUTICS, INC.
| WEREWOLF THERAPEUTICS, INC.
| LONGWOOD FUND V, L.P.
| IMMUNEID, INC.
| IMMUNITAS THERAPEUTICS, INC.
| LONGWOOD FUND VI, L.P.
| LONGWOOD SPECIAL SITUATIONS FUND, L.P.
| NEWLEOS THERAPEUTICS, INC.
THOMAS
WOIWODE
DIRECTOR
EURO VENTURES 4, INC.
| AUDENTES THERAPEUTICS, INC.
| KANYOS BIO, INC.
| INCEPTION IBD, INC.
| CRISPR THERAPEUTICS AG
| VERSANT VENTURE V AIV FEEDER HOLDINGS, L.P.
| VERSANT VENTURE V AIV, L.P.
| VERSANT VENTURE CAPITAL VI, L.P.
| TEMPEST THERAPEUTICS, INC.
| VERSANT VOYAGEURS I FEEDER, L.P.
| VERSANT VENTURE CAPITAL VII, L.P.
| VIVIDION THERAPEUTICS, INC.
| VERSANT VOYAGEURS I, L.P.
| VERSANT VOYAGEURS I PARALLEL, L.P.
| LYCIA THERAPEUTICS, INC.
| JENGU THERAPEUTICS, INC.
| VERSANT VANTAGE II, L.P.
| VERSANT VOYAGEURS II, L.P.
| VERSANT VOYAGEURS II (CANADA), L.P.
| VERSANT VENTURE CAPITAL VIII, L.P.
| VERSANT VENTURE CAPITAL VIII (CANADA), L.P.
| SANTA ANA BIO, INC.
| TEMPEST THERAPEUTICS, INC.
| VERSANT VOYAGEURS III, L.P.
| VERSANT VOYAGEURS III (CANADA), L.P.
| VERSANT VANTAGE III, L.P.
| VERSANT VANTAGE III (CANADA), L.P.
| VERSANT VENTURE CAPITAL IX, L.P.
| VERSANT VENTURE CAPITAL IX (CANADA), L.P.
| VERSANT VENTURE CAPITAL SPV I (SAB), L.P.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2026-05-29
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2013-03-18
D/A
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2012-06-21
D/A
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2012-06-21
D/A
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2012-06-21
D
BIOTECHNOLOGY
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835]
DECLINE TO DISCLOSE
Equity
2012-06-21
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#

